#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA2094261	F	MMV: Screen against Mtb, single point, non replicating, at 25uM	Mycobacterium tuberculosis	399		organism-based format	MMV Malaria Box
2.	ALA2094262	F	MMV: Screen against Mtb, single point, replicating, at 25uM	Mycobacterium tuberculosis	399		organism-based format	MMV Malaria Box
3.	ALA2028070	F	MMV: Inhibition of Plasmodium falciparum 3D7 at 5uM compound concentration.	Plasmodium falciparum	315		organism-based format	MMV Malaria Box
4.	ALA2028071	F	MMV: Inhibition of Plasmodium falciparum 3D7 (EC50).	Plasmodium falciparum	317		organism-based format	MMV Malaria Box
5.	ALA2028072	F	MMV: Inhibition of Plasmodium falciparum K1 (EC50).	Plasmodium falciparum	171		organism-based format	MMV Malaria Box
6.	ALA2028073	F	MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro).	Trypanosoma cruzi	400		organism-based format	MMV Malaria Box
7.	ALA2028074	F	MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro).	Trypanosoma brucei brucei	400		organism-based format	MMV Malaria Box
8.	ALA2028075	F	MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro).	Trypanosoma brucei rhodesiense	400		organism-based format	MMV Malaria Box
9.	ALA2028076	F	MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro.	Leishmania infantum	400		organism-based format	MMV Malaria Box
10.	ALA2028077	T	MMV: Cytotoxicity against human fibroblasts (MRC-5) cells.	Homo sapiens	400		cell-based format	MMV Malaria Box
11.	ALA1040691	F	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
12.	ALA1040692	F	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
13.	ALA1040693	T	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	Homo sapiens	5,614		cell-based format	Novartis Malaria Screening
14.	ALA1040694	F	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.		5,614		assay format	Novartis Malaria Screening
15.	ALA1789905	F	NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.	Plasmodium yoelii	4,416		organism-based format	Novartis Malaria Screening
16.	ALA2363023	F	MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 24 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.	Schistosoma mansoni	400		organism-based format	MMV Malaria Box
17.	ALA2363024	F	MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 48 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.	Schistosoma mansoni	400		organism-based format	MMV Malaria Box
18.	ALA2363025	F	MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 72 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.	Schistosoma mansoni	400		organism-based format	MMV Malaria Box
19.	ALA2448810	F	MMV: Compounds (1uM) were screened in a 72hr growth assay monitored by flow cytometry both in the presence and absence of supplemental isopentenyl pyrophosphate (IPP) 200uM. Compounds which fail to show anti-malarial activity when chemically rescued by IPP are therefore specific to the apicoplast. The values are expressed as the ratio of the corresponding activity with and without IPP, respectively.	Plasmodium falciparum	400		organism-based format	MMV Malaria Box
20.	ALA3137357	F	MMV: Cryptosporidium parvum oocysts (Iowa Strain) were prepared for use by treatment with 10 mM HCl (37 degrees C, 10 min) followed by 2 mM sodium taurocholate in phosphate-buffered saline (PBS) with Ca2+ and Mg2+ (16 degrees C, 10 min) in order to stimulate excystation. The high-throughput screen was carried out by inoculating >90% confluent human ileocecal adenocarcinoma (HCT-8) cells (ATCC) with ~5.5 x 10^3 primed oocysts per well. Experimental compounds or DMSO (vehicle) were added three hours after infection, and cells were incubated for 48 hours.	Cryptosporidium parvum	400		organism-based format	MMV Malaria Box